Business
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
Preclinical study anticipated to be published in 1H 2025 documenting combination’s additive and/or synergistic anti-inflammatory signal; Company will seek to
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\nPreclinical study anticipated to be published in 1H 2025 documenting combination’s additive and/or synergistic anti-inflammatory signal;\n\n\nCompany will seek to advance asset in neurodegenerative and autoimmune diseases through the next stages alongside a strategic partner\n\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory diseases. Sustained inflammatory responses driven by dysfunctional immune regulation is a hallmark of serious autoimmune and neurodegenerative diseases.\n\n\nCOYA 303 is an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist (GLP-1 RA) designed for subcutaneous administration. In a preclinical study, COYA 303 exhibited a dual immunomodulatory mechanism of action resulting in an additive/synergistic anti-inflammatory effect, which the Company believes was due to increased Treg function and suppressed pro-inflammatory myeloid cells and responder T cells. Coya intends to publish the results of this study in a peer-reviewed publication in the first half of 2025 and has filed several patent applications to protect the compound.\n\n\nCOYA 301 is the Company’s proprietary low-dose IL-2 that serves as a backbone adjuvant with standard of care agents and other novel pathways.\n\n\nFollowing the positive results of this study, Coya intends to continue ongoing strategic discussions to advance COYA 303 through IND-enabling studies and into the clinic. In support of these efforts, Coya is initiating translational studies in partnership with a major academic university.\n\n\n“COYA 303 is the most recent addition to Coya’s investigational pipeline. We believe that while GLP-1 RAs may have monotherapy benefits in reducing inflammation, the unique anti-inflammatory signature of the combination of GLP-1 RA and COYA 301 is supportive of opportunities that may generate significant shareholder value for Coya and a potential strategic partner,” stated COYA CEO Arun Swaminathan.\n\n\nAbout Coya Therapeutics, Inc.\nHeadquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotech...